These trends were observed in IL17-, IL9-, and IL4-producing CD4+T and CD8+T cells in the MS patients, irrespective of whether they had IFNβ or corticosteroids within 3 months of initiation of fingolimod, as shown in S3 Fig. Here, CD8A is linked to myeloid sarcoma.